{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:25:49Z","timestamp":1787160349364,"version":"build-2736575974"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,5,29]],"date-time":"2014-05-29T00:00:00Z","timestamp":1401321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s40263-014-0173-3","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T03:42:25Z","timestamp":1401248545000},"page":"731-742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions"],"prefix":"10.1007","volume":"28","author":[{"given":"Sahil","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeem","family":"Mahfooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noureldin","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,29]]},"reference":[{"issue":"9648","key":"173_CR1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"issue":"9","key":"173_CR2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1590\/S0004-282X2012000900016","volume":"70","author":"MJ Sa","year":"2012","unstructured":"Sa MJ. Physiopathology of symptoms and signs in multiple sclerosis. Arq Neuropsiquiatr. 2012;70(9):733\u201340.","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"173_CR3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1191\/1352458504ms993oa","volume":"10","author":"B Weinstock-Guttman","year":"2004","unstructured":"Weinstock-Guttman B, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler. 2004;10(2):170\u20135.","journal-title":"Mult Scler"},{"issue":"9","key":"173_CR4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/1352458510368985","volume":"16","author":"AP Hearn","year":"2010","unstructured":"Hearn AP, Silber E. Osteoporosis in multiple sclerosis. Mult Scler. 2010;16(9):1031\u201343.","journal-title":"Mult Scler"},{"issue":"7","key":"173_CR5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-1331.2005.00988.x","volume":"12","author":"M Zorzon","year":"2005","unstructured":"Zorzon M, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol. 2005;12(7):550\u20136.","journal-title":"Eur J Neurol"},{"issue":"17","key":"173_CR6","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1212\/WNL.0b013e3181beece8","volume":"73","author":"RA Marrie","year":"2009","unstructured":"Marrie RA, et al. A cross-sectional study of bone health in multiple sclerosis. Neurology. 2009;73(17):1394\u20138.","journal-title":"Neurology"},{"issue":"1\u20132","key":"173_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2009.09.012","volume":"287","author":"C Sioka","year":"2009","unstructured":"Sioka C, Kyritsis AP, Fotopoulos A. Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci. 2009;287(1\u20132):1\u20136.","journal-title":"J Neurol Sci"},{"issue":"12","key":"173_CR8","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00198-011-1644-8","volume":"22","author":"JC Gibson","year":"2011","unstructured":"Gibson JC, Summers GD. Bone health in multiple sclerosis. Osteoporos Int. 2011;22(12):2935\u201349.","journal-title":"Osteoporos Int"},{"issue":"1\u20132","key":"173_CR9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2012.03.026","volume":"319","author":"S Josyula","year":"2012","unstructured":"Josyula S, et al. The nervous system\u2019s potential role in multiple sclerosis associated bone loss. J Neurol Sci. 2012;319(1\u20132):8\u201314.","journal-title":"J Neurol Sci"},{"issue":"9","key":"173_CR10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/00207454.2013.785950","volume":"123","author":"S Ye","year":"2013","unstructured":"Ye S, Wu R, Wu J. Multiple sclerosis and fracture. Int J Neurosci. 2013;123(9):609\u201316.","journal-title":"Int J Neurosci"},{"issue":"4 Suppl B","key":"173_CR11","first-page":"S1","volume":"18","author":"S Levis","year":"2012","unstructured":"Levis S, Theodore G. Summary of AHRQ\u2019s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm. 2012;18(4 Suppl B):S1\u201315 (discussion S13).","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"173_CR12","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.51.4.1161","volume":"51","author":"F Cosman","year":"1998","unstructured":"Cosman F, et al. Fracture history and bone loss in patients with MS. Neurology. 1998;51(4):1161\u20135.","journal-title":"Neurology"},{"issue":"9","key":"173_CR13","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1212\/WNL.44.9.1687","volume":"44","author":"J Nieves","year":"1994","unstructured":"Nieves J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994;44(9):1687\u201392.","journal-title":"Neurology"},{"issue":"4","key":"173_CR14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00774-005-0604-9","volume":"23","author":"S Ozgocmen","year":"2005","unstructured":"Ozgocmen S, et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab. 2005;23(4):309\u201313.","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"173_CR15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1191\/1352458504ms1076oa","volume":"10","author":"A Achiron","year":"2004","unstructured":"Achiron A, et al. Bone strength in multiple sclerosis: cortical midtibial speed-of-sound assessment. Mult Scler. 2004;10(5):488\u201393.","journal-title":"Mult Scler"},{"issue":"2","key":"173_CR16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1212\/WNL.0b013e3182242d34","volume":"77","author":"SM Moen","year":"2011","unstructured":"Moen SM, et al. Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome. Neurology. 2011;77(2):151\u20137.","journal-title":"Neurology"},{"issue":"2","key":"173_CR17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-8529(05)70004-9","volume":"27","author":"RP Heaney","year":"1998","unstructured":"Heaney RP. Pathophysiology of osteoporosis. Endocrinol Metab Clin North Am. 1998;27(2):255\u201365.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9\u201310","key":"173_CR18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10354-009-0647-y","volume":"159","author":"W Sipos","year":"2009","unstructured":"Sipos W, et al. Pathophysiology of osteoporosis. Wien Med Wochenschr. 2009;159(9\u201310):230\u20134.","journal-title":"Wien Med Wochenschr"},{"issue":"3","key":"173_CR19","first-page":"146","volume":"81","author":"J Luis Neyro","year":"2013","unstructured":"Luis Neyro J, Jesus Cancelo M, Palacios S. Inhibition of RANK-L in the pathophysiology of osteoporosis. Clinical evidences of its use. Ginecol Obstet Mex. 2013;81(3):146\u201357.","journal-title":"Ginecol Obstet Mex"},{"issue":"11","key":"173_CR20","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.2489","volume":"17","author":"T Negishi-Koga","year":"2011","unstructured":"Negishi-Koga T, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17(11):1473\u201380.","journal-title":"Nat Med"},{"issue":"Suppl 6","key":"173_CR21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00415-008-6001-2","volume":"255","author":"T Korn","year":"2008","unstructured":"Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008;255(Suppl 6):2\u20136.","journal-title":"J Neurol"},{"issue":"5","key":"173_CR22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJM199502023320506","volume":"332","author":"SC Manolagas","year":"1995","unstructured":"Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332(5):305\u201311.","journal-title":"N Engl J Med"},{"issue":"4","key":"173_CR23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11914-009-0023-2","volume":"7","author":"RR McLean","year":"2009","unstructured":"McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009;7(4):134\u20139.","journal-title":"Curr Osteoporos Rep"},{"issue":"1\u20132","key":"173_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2008.08.031","volume":"276","author":"A Altintas","year":"2009","unstructured":"Altintas A, et al. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci. 2009;276(1\u20132):41\u20134.","journal-title":"J Neurol Sci"},{"issue":"4","key":"173_CR25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/1352458509359723","volume":"16","author":"MH Vogt","year":"2010","unstructured":"Vogt MH, et al. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler. 2010;16(4):443\u20139.","journal-title":"Mult Scler"},{"issue":"2","key":"173_CR26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2478\/folmed-2013-0011","volume":"55","author":"GS Slavov","year":"2013","unstructured":"Slavov GS, et al. Vitamin D immunomodulatory potential in multiple sclerosis. Folia Med (Plovdiv). 2013;55(2):5\u20139.","journal-title":"Folia Med (Plovdiv)"},{"issue":"1","key":"173_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1212\/01.WNL.0000101723.79681.38","volume":"62","author":"KL Munger","year":"2004","unstructured":"Munger KL, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60\u20135.","journal-title":"Neurology"},{"issue":"1","key":"173_CR28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2012.03.006","volume":"135","author":"PM George","year":"2012","unstructured":"George PM, et al. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135(1):44\u201353.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"173_CR29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.bcp.2009.01.007","volume":"77","author":"AK Abraham","year":"2009","unstructured":"Abraham AK, et al. Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 2009;77(12):1757\u201362.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"173_CR30","doi-asserted-by":"crossref","first-page":"e45703","DOI":"10.1371\/journal.pone.0045703","volume":"7","author":"SM Moen","year":"2012","unstructured":"Moen SM, et al. Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study. PLoS One. 2012;7(9):e45703.","journal-title":"PLoS One"},{"issue":"4","key":"173_CR31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1210\/endo.140.4.6637","volume":"140","author":"T Thomas","year":"1999","unstructured":"Thomas T, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140(4):1630\u20138.","journal-title":"Endocrinology"},{"issue":"4","key":"173_CR32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/jcb.10156","volume":"85","author":"JO Gordeladze","year":"2002","unstructured":"Gordeladze JO, et al. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002;85(4):825\u201336.","journal-title":"J Cell Biochem"},{"issue":"2","key":"173_CR33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0092-8674(00)81558-5","volume":"100","author":"P Ducy","year":"2000","unstructured":"Ducy P, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197\u2013207.","journal-title":"Cell"},{"issue":"9","key":"173_CR34","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1073\/pnas.0308744101","volume":"101","author":"F Elefteriou","year":"2004","unstructured":"Elefteriou F, et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA. 2004;101(9):3258\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"173_CR35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ajcn\/85.4.1121","volume":"85","author":"CE Ruhl","year":"2007","unstructured":"Ruhl CE, et al. Body mass index and serum leptin concentration independently estimate percentage body fat in older adults. Am J Clin Nutr. 2007;85(4):1121\u20136.","journal-title":"Am J Clin Nutr"},{"issue":"10 Pt 2","key":"173_CR36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1301\/002966402320634878","volume":"60","author":"JM Friedman","year":"2002","unstructured":"Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev. 2002;60(10 Pt 2):S1\u201314 (discussion S68\u201384, 85\u20137).","journal-title":"Nutr Rev"},{"issue":"4","key":"173_CR37","first-page":"1118","volume":"80","author":"HS Glauber","year":"1995","unstructured":"Glauber HS, et al. Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. J Clin Endocrinol Metab. 1995;80(4):1118\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3 Suppl","key":"173_CR38","doi-asserted-by":"crossref","first-page":"433S","DOI":"10.1093\/ajcn\/63.3.433","volume":"63","author":"GM Wardlaw","year":"1996","unstructured":"Wardlaw GM. Putting body weight and osteoporosis into perspective. Am J Clin Nutr. 1996;63(3 Suppl):433S\u20136S.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"173_CR39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.yhbeh.2012.04.010","volume":"62","author":"ED Carlton","year":"2012","unstructured":"Carlton ED, Demas GE, French SS. Leptin, a neuroendocrine mediator of immune responses, inflammation, and sickness behaviors. Horm Behav. 2012;62(3):272\u20139.","journal-title":"Horm Behav"},{"issue":"5","key":"173_CR40","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cell.2009.06.051","volume":"138","author":"VK Yadav","year":"2009","unstructured":"Yadav VK, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138(5):976\u201389.","journal-title":"Cell"},{"issue":"10","key":"173_CR41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2174\/1381612033455369","volume":"9","author":"MM Veniant","year":"2003","unstructured":"Veniant MM, LeBel CP. Leptin: from animals to humans. Curr Pharm Des. 2003;9(10):811\u20138.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"173_CR42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1172\/JCI26523","volume":"116","author":"V Rosa De","year":"2006","unstructured":"De Rosa V, et al. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J Clin Invest. 2006;116(2):447\u201355.","journal-title":"J Clin Invest"},{"issue":"10","key":"173_CR43","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.4049\/jimmunol.166.10.5909","volume":"166","author":"G Matarese","year":"2001","unstructured":"Matarese G, et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol. 2001;166(10):5909\u201316.","journal-title":"J Immunol"},{"issue":"2","key":"173_CR44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1472-8206.2009.00667.x","volume":"23","author":"S Budhiraja","year":"2009","unstructured":"Budhiraja S, Chugh A. Neuromedin U: physiology, pharmacology and therapeutic potential. Fund Clin Pharmacol. 2009;23(2):149\u201357.","journal-title":"Fund Clin Pharmacol"},{"issue":"10","key":"173_CR45","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm1640","volume":"13","author":"S Sato","year":"2007","unstructured":"Sato S, et al. Central control of bone remodeling by neuromedin U. Nat Med. 2007;13(10):1234\u201340.","journal-title":"Nat Med"},{"issue":"2","key":"173_CR46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bone.2011.10.001","volume":"50","author":"YC Shi","year":"2012","unstructured":"Shi YC, Baldock PA. Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. Bone. 2012;50(2):430\u20136.","journal-title":"Bone"},{"issue":"2","key":"173_CR47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11914-012-0102-7","volume":"10","author":"EC Khor","year":"2012","unstructured":"Khor EC, Baldock P. The NPY system and its neural and neuroendocrine regulation of bone. Curr Osteoporos Rep. 2012;10(2):160\u20138.","journal-title":"Curr Osteoporos Rep"},{"issue":"9","key":"173_CR48","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/jbmr.439","volume":"26","author":"H Inose","year":"2011","unstructured":"Inose H, et al. Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res. 2011;26(9):2002\u201311.","journal-title":"J Bone Miner Res"},{"key":"173_CR49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-med-090710-133426","volume":"62","author":"G Karsenty","year":"2011","unstructured":"Karsenty G, Yadav VK. Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med. 2011;62:323\u201331.","journal-title":"Annu Rev Med"},{"issue":"4","key":"173_CR50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000334095","volume":"19","author":"XQ Yuan","year":"2012","unstructured":"Yuan XQ, et al. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation. 2012;19(4):201\u20138.","journal-title":"Neuroimmunomodulation"},{"issue":"7032","key":"173_CR51","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature03398","volume":"434","author":"F Elefteriou","year":"2005","unstructured":"Elefteriou F, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514\u201320.","journal-title":"Nature"},{"issue":"3","key":"173_CR52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cmet.2010.01.005","volume":"11","author":"Y Shi","year":"2010","unstructured":"Shi Y, et al. Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metab. 2010;11(3):231\u20138.","journal-title":"Cell Metab"},{"issue":"2","key":"173_CR53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0021-9150(01)00570-6","volume":"158","author":"CJ Smith","year":"2001","unstructured":"Smith CJ, Fischer TH. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis. 2001;158(2):257\u201367.","journal-title":"Atherosclerosis"},{"issue":"2","key":"173_CR54","first-page":"89","volume":"58","author":"AC Didilescu","year":"2009","unstructured":"Didilescu AC, et al. The role of smoking in changing essential parameters in body homeostasis. Pneumologia. 2009;58(2):89\u201394.","journal-title":"Pneumologia"},{"issue":"12","key":"173_CR55","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archneur.1992.00530360041015","volume":"49","author":"M Emre","year":"1992","unstructured":"Emre M, de Decker C. Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch Neurol. 1992;49(12):1243\u20137.","journal-title":"Arch Neurol"},{"issue":"7","key":"173_CR56","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1212\/WNL.0b013e3181b2a706","volume":"73","author":"R Zivadinov","year":"2009","unstructured":"Zivadinov R, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology. 2009;73(7):504\u201310.","journal-title":"Neurology"},{"issue":"Pt 7","key":"173_CR57","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1093\/brain\/awt139","volume":"136","author":"A Manouchehrinia","year":"2013","unstructured":"Manouchehrinia A, et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain. 2013;136(Pt 7):2298\u2013304.","journal-title":"Brain"},{"issue":"1","key":"173_CR58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/aje\/154.1.69","volume":"154","author":"MA Hernan","year":"2001","unstructured":"Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol. 2001;154(1):69\u201374.","journal-title":"Am J Epidemiol"},{"issue":"12","key":"173_CR59","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/sj.ejcn.1600870","volume":"53","author":"C Brot","year":"1999","unstructured":"Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr. 1999;53(12):920\u20136.","journal-title":"Eur J Clin Nutr"},{"key":"173_CR60","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2741\/e575","volume":"4","author":"M Fini","year":"2012","unstructured":"Fini M, et al. Role of obesity, alcohol and smoking on bone health. Front Biosci (Elite Ed). 2012;4:2686\u2013706.","journal-title":"Front Biosci (Elite Ed)"},{"issue":"9","key":"173_CR61","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/00007256-200535090-00004","volume":"35","author":"KT Borer","year":"2005","unstructured":"Borer KT. Physical activity in the prevention and amelioration of osteoporosis in women: interaction of mechanical, hormonal and dietary factors. Sports Med. 2005;35(9):779\u2013830.","journal-title":"Sports Med"},{"issue":"6","key":"173_CR62","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1682\/JRRD.2007.10.0159","volume":"45","author":"MC Mojtahedi","year":"2008","unstructured":"Mojtahedi MC, et al. Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev. 2008;45(6):851\u201361.","journal-title":"J Rehabil Res Dev"},{"issue":"3","key":"173_CR63","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00415-009-5337-6","volume":"257","author":"LH Steffensen","year":"2010","unstructured":"Steffensen LH, Mellgren SI, Kampman MT. Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol. 2010;257(3):410\u20138.","journal-title":"J Neurol"},{"issue":"1","key":"173_CR64","first-page":"23","volume":"99","author":"RN Nijs De","year":"2008","unstructured":"De Nijs RN. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med. 2008;99(1):23\u201343.","journal-title":"Minerva Med"},{"issue":"10","key":"173_CR65","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1210\/jc.2004-0164","volume":"89","author":"A Dovio","year":"2004","unstructured":"Dovio A, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89(10):4923\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"173_CR66","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1191\/1352458503ms966oa","volume":"9","author":"S Tuzun","year":"2003","unstructured":"Tuzun S, et al. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler. 2003;9(6):600\u20134.","journal-title":"Mult Scler"},{"issue":"8","key":"173_CR67","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneur.1996.00550080071014","volume":"53","author":"SR Schwid","year":"1996","unstructured":"Schwid SR, et al. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol. 1996;53(8):753\u20137.","journal-title":"Arch Neurol"},{"issue":"6","key":"173_CR68","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1528-1157.1999.tb00772.x","volume":"40","author":"E Olafsson","year":"1999","unstructured":"Olafsson E, Benedikz J, Hauser WA. Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia. 1999;40(6):745\u20137.","journal-title":"Epilepsia"},{"issue":"4","key":"173_CR69","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000117350","volume":"30","author":"A Ghezzi","year":"1990","unstructured":"Ghezzi A, et al. Epilepsy in multiple sclerosis. Eur Neurol. 1990;30(4):218\u201323.","journal-title":"Eur Neurol"},{"issue":"9","key":"173_CR70","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1212\/01.wnl.0000180910.72487.18","volume":"65","author":"SJ Petty","year":"2005","unstructured":"Petty SJ, et al. Effect of antiepileptic medication on bone mineral measures. Neurology. 2005;65(9):1358\u201365.","journal-title":"Neurology"},{"issue":"1","key":"173_CR71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.amjopharm.2010.02.003","volume":"8","author":"RH Lee","year":"2010","unstructured":"Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010;8(1):34\u201346.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"2","key":"173_CR72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00415-012-6579-2","volume":"260","author":"A Truini","year":"2013","unstructured":"Truini A, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260(2):351\u201367.","journal-title":"J Neurol"},{"issue":"1","key":"173_CR73","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11910-012-0320-5","volume":"13","author":"C Solaro","year":"2013","unstructured":"Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13(1):320.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"173_CR74","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archinte.164.3.338-a","volume":"164","author":"HW Daniell","year":"2004","unstructured":"Daniell HW. OPioid osteoporosis. Arch Internal Med. 2004;164(3):338.","journal-title":"Arch Internal Med"},{"issue":"1","key":"173_CR75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1359\/jbmr.1998.13.1.88","volume":"13","author":"AM Elhassan","year":"1998","unstructured":"Elhassan AM, et al. Methionine-enkephalin in bone and joint tissues. J Bone Miner Res. 1998;13(1):88\u201395.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"173_CR76","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/JAD-2009-1185","volume":"18","author":"N Loskutova","year":"2009","unstructured":"Loskutova N, et al. Bone density and brain atrophy in early Alzheimer\u2019s disease. J Alzheimers Dis. 2009;18(4):777\u201385.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"173_CR77","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1177\/1352458512440206","volume":"18","author":"S Batista","year":"2012","unstructured":"Batista S, et al. Cognitive impairment is associated with reduced bone mass in multiple sclerosis. Mult Scler. 2012;18(10):1459\u201365.","journal-title":"Mult Scler"},{"issue":"1","key":"173_CR78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11845-008-0253-9","volume":"178","author":"M Shuhaibar","year":"2009","unstructured":"Shuhaibar M, et al. Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci. 2009;178(1):43\u20135.","journal-title":"Ir J Med Sci"},{"issue":"5","key":"173_CR79","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/1352458506070605","volume":"12","author":"B Weinstock-Guttman","year":"2006","unstructured":"Weinstock-Guttman B, et al. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler. 2006;12(5):541\u201350.","journal-title":"Mult Scler"},{"key":"173_CR80","unstructured":"National Osteoporosis Foundation. NOF\u2019s clinicians\u2019 guide to the prevention and treatment of osteoporosis ( http:\/\/nof.org\/hcp\/resources\/913 ."},{"issue":"7237","key":"173_CR81","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature07713","volume":"458","author":"M Ishii","year":"2009","unstructured":"Ishii M, et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature. 2009;458(7237):524\u20138.","journal-title":"Nature"},{"issue":"1","key":"173_CR82","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2012.05.130","volume":"423","author":"C Sato","year":"2012","unstructured":"Sato C, et al. Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation. Biochem Biophys Res Commun. 2012;423(1):200\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"173_CR83","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00441-011-1217-3","volume":"347","author":"C Huang","year":"2012","unstructured":"Huang C, et al. Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation. Cell Tissue Res. 2012;347(3):553\u201366.","journal-title":"Cell Tissue Res"},{"issue":"4","key":"173_CR84","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385\u201397.","journal-title":"Osteoporos Int"},{"key":"173_CR85","first-page":"528790","volume":"2012","author":"LJ Melton 3rd","year":"2012","unstructured":"Melton LJ 3rd, et al. Potential extensions of the US FRAX algorithm. J Osteoporos. 2012;2012:528790.","journal-title":"J Osteoporos"},{"issue":"6","key":"173_CR86","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bone.2012.02.639","volume":"50","author":"EM Dennison","year":"2012","unstructured":"Dennison EM, et al. Effect of co-morbidities on fracture risk: findings from the global longitudinal study of osteoporosis in women (GLOW). Bone. 2012;50(6):1288\u201393.","journal-title":"Bone"},{"issue":"9","key":"173_CR87","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.0b013e318266faae","volume":"79","author":"MT Bazelier","year":"2012","unstructured":"Bazelier MT, et al. A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis. Neurology. 2012;79(9):922\u20138.","journal-title":"Neurology"},{"issue":"2","key":"173_CR88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2217\/bmm.13.10","volume":"7","author":"P Sundstrom","year":"2013","unstructured":"Sundstrom P, Salzer J. Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention. Biomark Med. 2013;7(2):193\u20135.","journal-title":"Biomark Med"},{"issue":"1\u20132","key":"173_CR89","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2009.05.002","volume":"286","author":"KM Myhr","year":"2009","unstructured":"Myhr KM. Vitamin D treatment in multiple sclerosis. J Neurol Sci. 2009;286(1\u20132):104\u20138.","journal-title":"J Neurol Sci"},{"issue":"4","key":"173_CR90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/NRL.0b013e31825bbf35","volume":"18","author":"B Weinstock-Guttman","year":"2012","unstructured":"Weinstock-Guttman B, et al. Vitamin D and multiple sclerosis. Neurologist. 2012;18(4):179\u201383.","journal-title":"Neurologist"},{"issue":"3","key":"173_CR91","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","volume":"71","author":"A Ascherio","year":"2014","unstructured":"Ascherio A, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306\u201314.","journal-title":"JAMA Neurol"},{"key":"173_CR92","doi-asserted-by":"crossref","first-page":"a2397","DOI":"10.1136\/bmj.a2397","volume":"337","author":"Z Kmietowicz","year":"2008","unstructured":"Kmietowicz Z. NICE publishes osteoporosis guidance after more than six\u00a0years of consultation. BMJ. 2008;337:a2397.","journal-title":"BMJ"},{"issue":"2","key":"173_CR93","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1759720X09354945","volume":"1","author":"J Compston","year":"2009","unstructured":"Compston J. NICE: its influence in treating osteoporosis in the UK and beyond. Ther Adv Musculoskelet Dis. 2009;1(2):63\u20136.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"173_CR94","doi-asserted-by":"crossref","unstructured":"McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370(5):412-20","DOI":"10.1056\/NEJMoa1305224"},{"issue":"8","key":"173_CR95","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","volume":"362","author":"SR Cummings","year":"2010","unstructured":"Cummings SR, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686\u201396.","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"173_CR96","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1007\/s10072-003-0171-6","volume":"24","author":"M Trojano","year":"2003","unstructured":"Trojano M, et al. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci. 2003;24(Suppl 5):S268\u201370.","journal-title":"Neurol Sci"},{"issue":"12","key":"173_CR97","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","volume":"358","author":"BA Lenart","year":"2008","unstructured":"Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358(12):1304\u20136.","journal-title":"N Engl J Med"},{"issue":"19","key":"173_CR98","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black DM, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761\u201371.","journal-title":"N Engl J Med"},{"issue":"2","key":"173_CR99","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2009.03581.x","volume":"72","author":"CV Odvina","year":"2010","unstructured":"Odvina CV, et al. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol. 2010;72(2):161\u20138.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"173_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2014;29(1):1\u201323.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"173_CR101","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s002239900309","volume":"61","author":"CA Formica","year":"1997","unstructured":"Formica CA, et al. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int. 1997;61(2):129\u201333.","journal-title":"Calcif Tissue Int"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0173-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0173-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0173-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T22:29:58Z","timestamp":1565476198000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0173-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,29]]},"references-count":101,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["173"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0173-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,29]]}}}